301-400

301. Gheeraert PJ, De Buyzere ML, Taeymans YM, et al. Risk factors for primary ventricular fibrillation during acute myocardial infarction: a systematic

　review and meta-analysis. Eur Heart J 2006; 27: 2499-2510.

302. Bigger JT Jr, Dresdale RJ, Heissenbuttel RH, et al. Ventricular arrhythmias in ischemic heart disease: mechanism, prevalence, significance, and

　management. Prog Cardiovasc Dis 1977; 19: 255-300.

303. Volpi A, Cavalli A, Santoro E, et al. Incidence and prognosis of secondary ventricular fibrillation in acute myocardial infarction. Evidence for a

protective

　effect of thrombolytic therapy. GISSI Investigators. Circulation 1990; 82: 1279-1288.

304. Behar S, Reicher-Reiss H, Shechter M, et al. Frequency and prognostic significance of secondary ventricular fibrillation complicating acute myocardial

　infarction. SPRINT Study Group. Am J Cardiol 1993; 71: 152-156.

305. McMurray J, Køber L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct

　Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005; 45: 525-530.

306. Piccini JP, Hranitzky PM, Kilaru R, et al. Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular

　tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT]

　Registry). Am J Cardiol 2008; 102: 1427-1432.

307. Mont L, Cinca J, Blanch P, et al. Predisposing factors and prognostic value of sustained monomorphic ventricular tachycardia in the early phase of

　acute myocardial infarction.J Am Coll Cardiol 1996; 28: 1670-1676.

308. Goldberg RJ, Zevallos JC, Yarzebski J, et al. Prognosis of acute myocardial infarction complicated by complete heart block (the Worcester Heart

　Attack Study). Am J Cardiol 1992; 69: 1135-1141.

309. Berger PB, Ryan TJ. Inferior myocardial infarction. Highrisk subgroups. Circulation 1990; 81: 401-411.

310. 循環器病の診断と治療に関するガイドライン．急性冠症候群の治療に関するガイドライン．Circ J 2002; 66, Suppl. Ⅴ: 1121-1436.

311. Mukharji J, Rude RE, Poole WK, et al. Risk factors for sudden death after acute myocardial infarction: Two-year follow-up. Am J Cardiol 1984; 54:

　31-36.

312. Hallstrom AP, Cobb LA, Yu BH, et al. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and

　1985.Am J Cardiol 1991; 68: 1025-1031.

313. Greene HL.The CASCADE Study: r andomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. CASCADE Investigators. Am J

　Cardiol 1993; 72: 70F-74F.

314. Cheema AN, Sheu K, Parker M, et al. Nonsustained ventricular tachycardia in the setting of acute myocardial infarction: tachycardia characteristics

　and their prognostic implications. Circulation 1998; 98: 2030-2036.

315. Bigger JT Jr, Fleiss JL. Rolnitzky LM. Prevalence, characteristics and significance of ventricular tachycardia detected by 24-hour continuous

　electrocardiographic recordings in the late hospital phase of acute myocardial infarction. Am J Cardiol 1986; 58: 1151-1160.

316. Maggioni AP, Zuanetti G, Franzosi MG, et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the

　fibrinolytic era. GISSI-2 results. Circulation 1993; 87: 312-332.

317. Pedretti R, Etro MD, Laporta A, et al. Prediction of late arrhythmic events after acute myocardial infarction from combined use of noninvasive

　prognostic variables and inducibility of sustained monomorphic ventricular tachycardia. Am J Cardiol 1993; 71: 1131-1114.

318. Ohno J, Watanabe E, Toyama J, et al. Risk stratification and survival in post myocardial infarction patients: a large prospective and multicenter study

　in Japan. Int J Cardiol 2004; 93: 263-268.

319. Statters DJ, Malik M, Redwood S, et al. Use of ventricular premature complexes for risk stratification after acute myocardial infarction in the

　thrombolytic era. Am J Cardiol 1996; 77: 133-138.

320. Hallstrom AP, Bigger JT Jr, Roden D, et al. Prognostic significance of ventricular premature depolarizations measured 1 year after myocardial

　infarction in patients with early postinfarction asymptomatic ventricular arrhythmia. J Am Coll Cardiol 1992; 20: 259-264.

321. Kostis JB, Byington R, Friedman LM, et al. Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. J Am

　Coll Cardiol 1987; 10: 231-242.

322. Bourke JP, Richards DAB, Ross DL, et al. Routine programmed electrical stimulation in survivors of acute myocardial infarction for prediction of

　spontaneous ventricular tachyarrhythmias during follow-up: results, optimal stimulation protocol and cost-effective screening. J Am Coll Cardiol 1991; 18:

　780-788.

323. Santini M, Russo M, Botto G, et al. Clinical and arrhythmic outcomes after implantation of a defibrillator for primary prevention of sudden death in

　patients with post-myocardial infarction cardiomyopathy: The Survey to Evaluate Arrhythmia Rate in High-risk MI patients (SEARCH-MI). Europace 2009;

　11: 476-482.

324. Piccini JP, Berger JS, O’Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur

　Heart J 2009; 30: 1245-1253.

325. Hohnloser SH, Franck P, Klingenheben T, et al. Open infarct artery, late potentials and other prognostic factors in patients after actute myocardial

　infarction in the thrombolytic era. A prospective trial. Circulation 1994; 90: 1747-1756.

326. de Chillow C, Sadoul N, Bizwau O, et al. Prognostic value of thrombolysis, coronary artery patency, signal averaged electrocardiographic monitoring

　for life-threatening ventricular arrhythmias after a first acute myocardial infarction. Am J Cardiol 1997; 80: 852-858.

327. Holmes DR Jr, Davis KB, Mock MB, et al. The effect of medical and surgical treatment on subsequent sudden cardiac death in patients with coronary

　artery disease: A report from the Coronary Artery Surgery Study. Circulation 1986; 73: 1254-1263.

328. Gottlieb SO, Gottlieb SH, Achuff SC, et al. Silent ischemia on Holter monitoring predicts mortality in high-risk postinfarction patients. JAMA 1988;

　259: 1030-1035.

329. Davies RF, Goldberg AD, Forman S, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: Outcomes of patients randomized

　to initial strategies of medical therapy versus revascularization. Circulation 1997; 95: 2037-2043.

330. Weiner DA, Ryan TJ, McCabe CH, et al. Risk of developing an acute myocardial infarction or sudden coronary death in patients with exercise-induced

　silent myocardial ischemia. A report from the Coronary Artery Surgery Study (CASS) registry. Am J Cardiol 1988; 62: 1155-1158.

331. Igarashi Y, Tamura Y, Suzuki K, et al. High prevalence of coronary artery spasm in survivors of cardiac arrest with no apparent heart disease. Jpn

　Heart J 1992; 33: 653-663.

332. Nishizaki M, Arita M, Sakurada H, at al. Polymorphic ventricular tachycardia in patients with vasospastic anginaclinical and electrocardiographic

　characteristics and longterm outcome. Jpn Circ J 2001; 65: 519-525.

333. Yasue H, Takizawa A, Nagao M, et al. Long-term prognosis for patients with variant angina and influential factors. Circulation 1988; 78: 1-9.

334. 循環器病の診断と治療に関するガイドライン．肥大型心筋症の診療に関するガイドライン（2007年改訂版）．http://www.j-circ.or.jp/guideline/pdf/JCS2007

　_doi_h.pdf（2010年6月閲覧）．

335. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document

　on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and

　the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003; 42: 1687-1713.

336. 木村彰方．肥大型・拡張型心筋症の分子遺伝学．ゲノム医学 2003; 3: 9-16.

337. Arad M, Seidman J G, Seidman C. Phenotypic diversity in hypertrophic cardiomyopathy. Human Molecular Genetics 2002; 11: 2499-2506.

338. 室　愛子，古賀義則，西　宏文，他．肥大型心筋症の予後予測因子としての左室流出路狭窄の重要性．心臓 2000; 32: 404-411.

339. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy; Identification of high risk patients. J Am Coll Cardiol 2000; 36:

　2212-2218.

340. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death. Circulation 2000; 102: 858-864.

341. Kofflard MJM, Ten Cate FJ, van der Lee C, et al. Hypertrophic cardiomyopathy in a large community-based population : Clinical outcome and

　identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol 2003; 41: 987- 993.

342. Maron BJ, Shen W-K, Link MS, et al. Efficacy of implantable cardioverter- defibrillators for the prevention of sudden death in patients with hypertrophic

　cardiomyopathy. N Eng J Med 2000; 342: 365-373.

343. Cecchi F, Maron BJ. Epstein SE: Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J

　Am Coll Cardiol 1989; 13: 1283-1288.

344. Maron BJ, Spirito P, Shen W-K, et al. Implantable Cardioverter-Defibrillators and Prevention of Sudden Cardiac Death in Hypertrophic

Cardiomyopathy. JAMA 2007; 298: 405-412.

345. McKenna W,Deanfield J, Faruqui A, et al. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic

　features. Am J Cardiol 1981; 47: 532-538.

346. Priori SG, Aliot E, Blomstrom-Lundzvist C, et al. Task force on sudden cardiac death of the European Society of Cardiology. Eur Heart J 2001; 22:

　1374-1450.

347. McKenna WJ, Behr ER. Hypertrophic cardiomyopathy : management, risk stratification and prevention of sudden death. Heart 2002; 87: 169-176.

348. Maron BJ, Estes ⅢNAM., Maron MS, et al. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy.

　Circulation 2003; 107: 2872-2875.

349. Maron BJ, Casey SA, Poliac LC, et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999; 281: 650-655.

350. Maron BJ, Savage DD, Wolfson JK, et al. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic

　cardiomyopathy: a prospective study. Am J Cardiol 1981; 48: 252-257.

351. Spirito P, Rapezzi C, Autore C, et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular

　tachycardia Circulation 1994; 90:2743-2747.

352. McKenna WJ, Camm AJ. Sudden death in hypertrophic cardiomyopathy. Assessment of patients at high risk. Circulation 1989; 80: 1489-1492.

353. McKenna WJ, Oakley CN, Krikler DM, et al. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular

　tachycardia. Br Heart J 1985; 53: 412-416.

354. Savage DD, Seides SF, Maron BJ, et al. Epstein SE. Prevalence of arrhythmias during 24-hour electro cardiographic monitoring and exercise testing

　in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation 1979; 59: 866-875.

355. McKenna WJ, England D, Doi YL, et al. Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis. Br Heart J 1981; 46: 168-172.

356. Monserrat L, Elliot PM, Gimeno JR, et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden

　death risk in young patients. J Am Coll Cardiol 2003; 42: 873-879.

357. Stewart JT, McKenna WJ. Arrhythmias in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 1991; 2: 516-524.

358. McKenna WJ, Chetty S, Oakley CM, et al. Arrhythmia in hypertrophic cardiomyopathy: exercise and 48 hour ambulatory electrocardiographic

　assessment with and without beta adrenergic blocking therapy. Am J Cardiol 1980; 45: 1-5.

359. Cecchi F, Olivotto I, Montereggi A. Prognostic value of non-sustained ventricular tachycardia and potential role of amiodarone treatment in

hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart 1998; 79: 331-336.

360. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J

　Med 2000; 342: 1778-1785.

361. Elliott PM, Gimeno Blanes JR, Mahon NG, et al. Relation between severity of left ventricular hypertrophy and prognosis in patients with hypertrophic

　cardiomyopathy. Lancet 2001; 357: 420-424.

362. Casey SA, et al. Relation of extreme left ventricular hypertrophy to age in hypertrophic cardiomyopathy. Am J Cardiol 2003; 91: 626-628.

363. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Eng J

　Med 2003; 348: 295-303.

364. Koga Y, Kato A., Matsuyama K, et al. Disappearance of giant negative T waves in patients with the Japanese form of apical hypertrophy. J Am Coll

　Cardial 1995; 26: 1672-1678.

365. Okishige K, Sasano T, Yano K, et al. Serious arrhythmias in patients with apical hypertrophic cardiomyopathy. Intern Med 2001; 40: 396-402.

366. Olivotto I, Maron BJ, Montereggi A, et al. Prognostic value of systemic blood pressure response during exercise in a community-based patient

　population with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33: 2044-2051.

367. Kuck KH, Kunze KP, Schluter M, et al. Programmed electrical stimulation in hypertrophic cardiomyopathy. Results in patients with and without

　cardiac arrest or syncope. Eur Heart J 1988; 9: 177-185.

368. Watson RM, Schwartz JL, Maron BJ, et al. Inducible polymorphic ventricular tachycardia and ventricular fibrillation in a subgroup of patients with

　hypertrophic cardiomyopathy at high risk for sudden death. J Am Coll Cardiol 1987; 10: 761-774.

369. Zhu DWX, Sun H, Hill R, et al. Roberts R. The value of electrophysiology study and prophylactic implantation of cardioverter defibrillator in patients

　with hypertrophic cardiomyoathy. PACE 1998; 21: 299-302.

370. Watkins H, Rosenzweig A, Hwang DS, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic

　cardiomyopathy. N Engl J Med 1992; 326: 1108-1114.

371. Anan R, Greve G, Thierfelder L, et al. Prognostic implications of novel β -cardiac myosin heavy chain gene mutations that cause familial hypertrophic

　cardiomyopathy. J Clin Invest 1994; 93: 280-285.

372. Watkins H. Multiple disease genes cause hypertrophic cardiomyopathy. Br Heart J 1994; 72 (Suppl) : S4-S9.

373. Marian AJ, Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopahy. Circulation 1995; 92: 1336-1347.

374. Schwartz K, Carrier L, Guicheney P, et al. Molecular basis of familial cardiomyopathies. Circulation 1995; 91: 532-540.

375. Koga Y, Toshima H, Kimura A, et al . Clinical manifestations of hypertrophic cardiomyopathy with mutations in the cardiac beta-myosin heavy chain

　gene or cardiac troponin T gene. J Cardiac Failure 1996; 2 (Suppl 4): S97-S103.

376. Ackerman MJ, VanDriest SL, Ommen SR, et al. Prevalence and age-dependence of malignant mutations in the betamyosin heavy chain and troponin

　T genes in hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39: 2042-2048.

377. Verdecchia P, Schillaci G, Borgioni C, et al. Porcellati C. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular

　hypertrophy in essential hypertension. J Am Coll Cardiol 1998; 31: 383-390.

378. Lip GYH, Felmeden DC, Li -Saw-Hee FL, et al . Hypertensive heart diseese: a complex syndrome or a hypertensive cardiomyopathy? Eur Heart J

　2000; 21: 1653-1665.

379. Tin LL, Beevers G, Lip GYH. Hypertension, left ventricular hypertrophy and sudden death. Current Cardiology Reports 2002; 4: 449-457.

380. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart

　Study. N Engl J Med 1990, 322: 1561-1566.

381. Dunn FG, Mclenachan J, Isles CG, et al. Left ventricular hypertrophy and mortality in hypertension: an analysis of data from the Glasgow Blood

　Pressure Clinic. J Hypertens 1990; 8: 775-782.

382. Messerli FH, Grodzicki T. Hypertension, left ventricular hypertrophy, ventricular arrhythmias and sudden death. Eur Heart J 1992; 13 (Suppl D): 66-69.

383. Haider AW, Larson MG, Benjamin EJ, et al. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J

　Am Coll Cardiol 1998; 32: 1454-1459.

384. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001, 141: 334-341.

385. Messerli FH, Ventura HO, Elizardi DJ, et al. Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy. Am J

　Med 1984; 77: 18-22.

386. McLenachan JM, Henderson E, Morris KI, et al. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 1987;

　13: 787-792.

387. Ghali JK, Kadakia S, Cooper RS, et al. Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease. J

　Am Coll Cardiol 1991; 17: 1277-1282.

388. Greenberg MD, Papademetriou V, Nangan P, et al. Nonsustained ventricular tachycardia as a predictor events in black men with hypertensive LVH. J

　Clin Hypertens (Greenwich) 2000; 2: 14-19.

389. Kannel WB, Levy D, Cupples LA. Left ventricular hypertrophy and risk of cardiac failure. Insights from the Framingham Study. J Cardiovasc Pharmacol

　1987; 10 (Suppl 6): S135-140.

390. Levy D, Larson MG, Vasan RS, et al. Progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-1562.

391. Sharma S, Maron BJ, Whyte G, et al. Physiologic limits of left ventricular hypertrophy in elite junior athletes: Relevance to differential diagnosis of

　athlete’s heart and hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 40: 1431-1436.

392. Dec GW, Fuster V. Medical progress: idiopathic dilated cardiomyopathy. N Engl J Med 1994; 331: 564-575.

393. Fuster V, Gersh BJ, Giuliani ER, et al. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981; 47: 525-531.

394. Dries DL, Exner DV, Gersh BJ, et al. Radical differences in the outcome of left ventricular dysfunction. N Engl J Med 1999; 340: 609-616.

395. Huang S, Messer J, Denes P. Significance of ventricular tachycardia in idiopathic di lated cardiomyopathy: Observation in 35 patients. Am J Cardiol

　1982; 51: 507-512.

396. Meinertz T, Hofmann T, Kasper W, et al. Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol 1984; 53: 902-907.

397. Olshausen K, Stienen U, Schwarz F, et al. Long-term prognositic significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J

　Cardiol 1988; 61: 146-151.

398. Grimm W, Christ M, Bach J, et al. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg

　Cardiomyopathy Study. Circulation 2003; 108: 2883-2891.

399. Grimm W, Hoffmann JJ, Muller HH, et al. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained

　ventricular tachycardia on holter and a left ventricular ejection fraction below 30%. J Am Coll Cardiol 2002; 39: 780-787.

400. Iwata M, Yoashikawa T, Baba A, et al. Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular

　tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2001; 37: 418-424.

文献